Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.
Hyperactivity of 5 alpha-reductase in the skin is considered a major mechanism of excessive hair growth in hirsute women with normal levels of serum androgens (idiopathic hirsutism). Preventing the conversion of testosterone to dihydrotestosterone by inhibiting 5 alpha-reductase activity could thus be the most rational and effective treatment in this condition. The present study evaluated the effects of the oral administration of finasteride (5 mg once daily) for 6 months in 17 young women with idiopathic hirsutism, 5 of whom were also given an oral contraceptive. The degree of hirsutism (graded by a modified Ferriman-Gallwey score), serum sex hormone levels, and serum and urinary 5 alpha-metabolism steroid profiles were determined basally and periodically during the treatment period. The modified Ferriman-Gallwey score showed a remarkable reduction after 6 months of finasteride treatment (5.9 +/- 0.6 vs. 11.7 +/- 1.3; P < 0.01). Serum 5 alpha-dihydrotestosterone and 3 alpha-androstanediol glucuronide levels were decreased, and urinary C19 and C21 5 beta/5 alpha metabolite ratios were increased compared with pretreatment values. No significant adverse effect was reported. In women treated with finasteride and oral contraceptive, clinical efficacy was slightly more pronounced. In conclusion, the 5 alpha-reductase inhibitor finasteride is well tolerated and seems to be a useful tool in the treatment of idiopathic hirsutism.
Division of Metabolic Diseases, University of Verona, Italy.
P
P
Moghetti
R
R
Castello
C M
CM
Magnani
F
F
Tosi
C
C
Negri
D
D
Armanini
G
G
Bellotti
M
M
Muggeo
D000328:Adult; D000728:Androgens / Q000097:blood; D042944:Cholestenone 5 alpha-Reductase; D003276:Contraceptives, Oral / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use*; D006628:Hirsutism / Q000097:blood* / Q000188:drug therapy*; D006728:Hormones / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*
D000728:Androgens; D003276:Contraceptives, Oral; D006728:Hormones; D018120:Finasteride; D007986:Luteinizing Hormone; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase